Here are the 10-Q quarterly reports from Seaport Therapeutics, Inc. (SPTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPTX filings page.
Seaport Therapeutics, Inc. reported a third-quarter net loss of $26.4 million, versus $22.5 million a year earlier, and research and development expense of $23.9 million versus $20.5 million. For the first nine months of 2026, net loss was $114.4 million versus $50.7 million in 2025; operating cash used was $69.0 million versus $51.3 million. Nine-month general and administrative expense included $39.1 million of non-cash stock-based compensation.
As of September 30, 2026, Seaport had $403.8 million in cash, cash equivalents and investments; management believes this will fund operations for at least twelve months from issuance of the statements. The company completed its IPO in May 2026, selling 14,446,658 shares at $18.00 each for $238.4 million in net proceeds. Its preferred stock converted into 36,272,475 common shares at the IPO closing.
Seaport has no product-sales revenue and remains focused on clinical development. The Phase 2b BUOY-1 trial of GlyphAllo is underway, with topline data expected in the first half of 2027. Seaport reported that evening GlyphAllo dosing did not impair next-morning driving performance versus placebo in a Phase 1 simulation. It dosed the first patient in a GlyphAgo Phase 2a trial in October 2026 and expects topline data in early 2028.
Seaport Therapeutics, a clinical-stage neuropsychiatry company using its proprietary Glyph platform, reported a net loss of $62.6 million for Q2 2026 and $88.0 million for the first half of 2026. Year-to-date operating expenses were $93.4 million, including $46.0 million in research and development and $47.3 million in general and administrative costs. G&A expenses reflect substantial non-cash stock-based compensation, including $37.6 million in general and administrative awards and $1.8 million in research and development.
Liquidity improved following the IPO. As of June 30, 2026, total assets were $441.7 million, including $427.3 million of cash, cash equivalents and U.S. Treasury investments, which management believes will fund operations for at least twelve months. During Q2 2026, the company completed its IPO, issuing 14,446,658 shares at $18.00 per share for approximately $238.4 million in net proceeds, and all preferred stock converted into common shares, resulting in 53,530,550 common shares outstanding.
Pipeline programs advanced. Lead candidate GlyphAllo is in the Phase 2b BUOY-1 trial in major depressive disorder, with topline data expected in the first half of 2027, and a Phase 1 driving simulation study reading out in the second half of 2026. GlyphAgo completed Phase 1 with favorable pharmacokinetics and safety, with Phase 2 trials in generalized anxiety disorder planned from late 2026.
Seaport Therapeutics, Inc. is a clinical‑stage biotech developing oral therapies for depression, anxiety and other neuropsychiatric disorders using its Glyph platform. For the quarter ended March 31, 2026, it reported a net loss of $25.4 million, wider than $13.1 million a year earlier, driven mainly by higher research and development spending.
R&D expenses nearly doubled to $21.4 million as the company advanced its lead candidate GlyphAllo into a Phase 2b BUOY‑1 trial in major depressive disorder and ran supporting studies, while GlyphAgo progressed through Phase 1 with favorable bioavailability and safety data. General and administrative expenses were $6.1 million, reflecting public‑company preparation and growth in corporate infrastructure.
Seaport ended the quarter with $52.9 million in cash and cash equivalents and $159.7 million in U.S. Treasury investments, totaling $212.6 million in cash and investments. Management states that, combined with approximately $238.7 million of net proceeds from its second‑quarter 2026 IPO, these resources are expected to fund operations into 2029 while the pipeline advances through multiple planned Phase 2 trials.